AstraZeneca’s Dato-DXd BLA Accepted for Priority Review (AZN: NASDAQ)


The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s biologics license application for priority review of its drug datopotamab deruxtecan, also known as Dato-DXd, for the treatment of EGFR-mutated lung cancer.

Companies seek to have Dato-DXd approval



Source link

  • Related Posts

    Investment manager bet big on PTCT stock, adds 41,000 shares, according to recent SEC filing

    Palo Alto Investors LP reported a purchase of 41,303 shares of PTC therapeutics (NASDAQ:PTCT) in its SEC filing on February 17, 2026, with an estimated transaction value of $3.00 million…

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to continue. A required part of this site could not load. This could be due to a browser extension,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *